Zewge Shiferaw-Deribe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zewge Shiferaw-Deribe has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Tsering Dolkar
Internal Medicine, One Brooklyn Health (OBH) Interfaith Medical Center, Brooklyn, USA
2 shared publications - Aakriti Shrestha
Interfaith Medical Center, New York, USA
1 shared publication Abubaker M. Hamad
Medicine, Memorial Hospital of Converse County, Douglas, USA
1 shared publication- Aditya Keerthi Rayapureddy
Department of Internal Medicine, One Brooklyn Health- Interfaith Medical Center, NY
1 shared publication - Ferdous Salauddin1 shared publication
Fnu Jitidhar
Internal Medicine, One Brooklyn Health (OBH) Interfaith Medical Center, Brooklyn, USA
1 shared publication
Latest Publications
- Open Access
- 5 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27715
Fluctuating Hyperthyroidism and Hypothyroidism in Graves’ Disease: The Swinging Between Two Clinical Entities
Autoimmune thyroid disorders are frequently encountered in clinical practice and consist of a spectrum ranging from Graves’ hyperthyroidism to Hashimoto's hypothyroidism. Generally, patients with autoimmune thyroid disorders will lean towards one end of the spectrum or the other, with fluctuations between hyper- and hypothyroidism rarely seen. This is especially the case when persistent hyperthyroidism occurs after a prolonged period of hypothyroidism. Here, we present a case of a young female patient initially presenting with Graves’ disease with a previous history of hypothyroidism.
- 5 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27715
Open AccessFluctuating Hyperthyroidism and Hypothyroidism in Graves’ Disease: The Swinging Between Two Clinical Entities
Autoimmune thyroid disorders are frequently encountered in clinical practice and consist of a spectrum ranging from Graves’ hyperthyroidism to Hashimoto's hypothyroidism. Generally, patients with autoimmune thyroid disorders will lean towards one end of the spectrum or the other, with fluctuations between hyper- and hypothyroidism rarely seen. This is especially the case when persistent hyperthyroidism occurs after a prolonged period of hypothyroidism. Here, we present a case of a young female patient initially presenting with Graves’ disease with a previous history of hypothyroidism.
- Open Access
- 16 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26924
Painless Subacute Thyroiditis in a Patient With Acute COVID-19 Infection: A Transient Event
Coronavirus 2019 disease (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). Although several articles have described the non-respiratory effects of COVID-19 in the past two years, there are few reports of COVID-19 associated with thyroiditis. We present a case of a middle-aged female patient with positive COVID-19 PCR associated with acute pulmonary embolism and thyroiditis. Three months ago, her baseline thyroid profile was normal. Thyroiditis induced elevated free thyroxine (FT4) and decreased thyroid-stimulating hormone (TSH) levels resolved with conservative management within six days.
- 16 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26924
Open AccessPainless Subacute Thyroiditis in a Patient With Acute COVID-19 Infection: A Transient Event
Coronavirus 2019 disease (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). Although several articles have described the non-respiratory effects of COVID-19 in the past two years, there are few reports of COVID-19 associated with thyroiditis. We present a case of a middle-aged female patient with positive COVID-19 PCR associated with acute pulmonary embolism and thyroiditis. Three months ago, her baseline thyroid profile was normal. Thyroiditis induced elevated free thyroxine (FT4) and decreased thyroid-stimulating hormone (TSH) levels resolved with conservative management within six days.
- Open Access
- 1 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25588
Subclinical Hypothyroidism Presenting as Myxedema Coma: Case Report and Literature Review
Myxedema coma is a medical emergency with a high mortality rate. Patients with hypothyroidism may develop myxedema coma if left untreated, although quite rare nowadays owing to regular TSH (thyroid stimulating hormone) monitoring. We present the case of a patient with a known history of subclinical hypothyroidism, defined by normal free T4 (thyroxine) and high TSH, who was found to be in myxedema coma. Clinically, the patient was found to be lethargic, bradycardic, and hypothermic, and in the background of high TSH, myxedema coma was suspected. The patient was admitted to the ICU (Intensive Care Unit) and initially treated with intravenous (IV) hydrocortisone for possible concomitant adrenal insufficiency. This was followed by treatment with IV levothyroxine.
- 1 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25588
Open AccessSubclinical Hypothyroidism Presenting as Myxedema Coma: Case Report and Literature Review
Myxedema coma is a medical emergency with a high mortality rate. Patients with hypothyroidism may develop myxedema coma if left untreated, although quite rare nowadays owing to regular TSH (thyroid stimulating hormone) monitoring. We present the case of a patient with a known history of subclinical hypothyroidism, defined by normal free T4 (thyroxine) and high TSH, who was found to be in myxedema coma. Clinically, the patient was found to be lethargic, bradycardic, and hypothermic, and in the background of high TSH, myxedema coma was suspected. The patient was admitted to the ICU (Intensive Care Unit) and initially treated with intravenous (IV) hydrocortisone for possible concomitant adrenal insufficiency. This was followed by treatment with IV levothyroxine.
- Open Access
- 4 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e20938
Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide
The objective of this report is to discuss a case of drug-induced acute pancreatitis in a patient on a combination of dulaglutide and glipizide. The patient was a 61-year-old African American male with a past medical history of diabetes mellitus type 2 and essential hypertension, who was admitted for acute pancreatitis after presenting with upper abdominal pain. He was initially on glipizide but dulaglutide was added to improve control. The patient was a social drinker and an ex-cigarette smoker. He had serum lipase greater than 900 U/L, serum alcohol was negative, and abdominal computed tomography reported significant pancreatic edema consistent with acute pancreatitis but without features of necrotizing pancreatitis and no evidence of cholelithiasis or choledocholithiasis. His clinical state deteriorated after being complicated by paralytic ileus. He was managed conservatively, improved clinically, and was discharged home. Seeing that the incidence of pancreatitis is higher in patients with diabetes when compared to non-diabetics, it is important to counsel and monitor patients for risk factors of pancreatitis including medications. In the absence of other common causes in this case and considering the temporal relationship between presentation and the addition of dulaglutide to ongoing glipizide regimen, the combination of both drugs may have induced acute pancreatitis.
- 4 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e20938
Open AccessCase Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide
The objective of this report is to discuss a case of drug-induced acute pancreatitis in a patient on a combination of dulaglutide and glipizide. The patient was a 61-year-old African American male with a past medical history of diabetes mellitus type 2 and essential hypertension, who was admitted for acute pancreatitis after presenting with upper abdominal pain. He was initially on glipizide but dulaglutide was added to improve control. The patient was a social drinker and an ex-cigarette smoker. He had serum lipase greater than 900 U/L, serum alcohol was negative, and abdominal computed tomography reported significant pancreatic edema consistent with acute pancreatitis but without features of necrotizing pancreatitis and no evidence of cholelithiasis or choledocholithiasis. His clinical state deteriorated after being complicated by paralytic ileus. He was managed conservatively, improved clinically, and was discharged home. Seeing that the incidence of pancreatitis is higher in patients with diabetes when compared to non-diabetics, it is important to counsel and monitor patients for risk factors of pancreatitis including medications. In the absence of other common causes in this case and considering the temporal relationship between presentation and the addition of dulaglutide to ongoing glipizide regimen, the combination of both drugs may have induced acute pancreatitis.